Jian-jun Chu

Jian-jun Chu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
YXYang Xu
Yang Xu
HLHao Lin
Hao Lin
ZGZhe Gao
Zhe Gao
RGRui Guo
Rui Guo
YKYu-Chen Kan
Yu-Chen Kan
JCJian-jun Chu
Jian-jun Chu
A robust and easily manufactured high-strength and long-term release hydrazone-based isoniazid acrylic (HIA) bone cement is reported. The mechanical strength of HIA bone cement is similar to that of normal polymethyl methacrylate (PMMA) bone cement, far surpassing that of traditional isoniazid-containing antibiotic-loaded bone cement (INH bone cement). Isoniazid is connected to the bone cement through bioorthogonal hydrazone chemistry, and it possesses release properties superior to those of INH bone cement, allowing for the sustained release of isoniazid for up to 12 weeks. In vivo and in vitro studies also indicate that HIA cement exhibits better biocompatibility than INH bone cement. The results of this study not only signify progress in the realm of antimicrobial bone cement for addressing bone tuberculosis but also enhance our capacity to create and comprehend high-performing antimicrobial bone cement.

28 May 2024 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
RGRui Guo
Rui Guo
YKYu-Chen Kan
Yu-Chen Kan
YXYang Xu
Yang Xu
LHLu-Yang Han
Lu-Yang Han
WBWen-Han Bu
Wen-Han Bu
JCJian-jun Chu
Jian-jun Chu
Introduction: Our objective in this study was to prepare a novel type of polymethyl methacrylate (PMMA) bone cement, analyze its material properties, and evaluate its safety and antibacterial efficacy.Methods: A halamine compound methacrylate antibacterial PMMA bone cement containing an N-Cl bond structure was formulated, and its material characterization was determined with Fourier transform infrared spectroscopy (FT-IR) and 1H-NMR. The antibacterial properties of the material were studied using contact bacteriostasis and releasing-type bacteriostasis experiments. Finally, in vitro and in vivo biocompatibility experiments were performed to analyze the toxic effects of the material on mice and embryonic osteoblast precursor cells (MC3T3-E1).Results: Incorporation of the antibacterial methacrylate monomer with the N-halamine compound in the new antibacterial PMMA bone cement significantly increased its contact and releasing-type bacteriostatic performance against Staphylococcus aureus. Notably, at 20% and 25% additions of N-halamine compound, the contact and releasing-type bacteriostasis rates of bone cement samples reached 100% (p < 0.001). Furthermore, the new antibacterial bone cement containing 5%, 10%, and 15% N-halamine compounds showed good biocompatibility in vitro and in vivo.Conclusion: In this study, we found that the novel antibacterial PMMA bone cement with N-halamine compound methacrylate demonstrated good contact and releasing-type bacteriostatic properties against S. aureus. In particular, bone cement containing a 15% N-halamine monomer exhibited strong antibacterial properties and good in vitro and in vivo biocompatibility.

6 March 2024 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
YKYu-Chen Kan
Yu-Chen Kan
RGRui Guo
Rui Guo
YXYang Xu
Yang Xu
LHLu-Yang Han
Lu-Yang Han
WBWen-Han Bu
Wen-Han Bu
JCJian-jun Chu
Jian-jun Chu
Objective: The objective of this study is to investigate the impact of four natural product extracts, namely, aloe-emodin, quercetin, curcumin, and tannic acid, on the in vitro bacteriostatic properties and biocompatibility of gentamicin-loaded bone cement and to establish an experimental groundwork supporting the clinical utility of antibiotic-loaded bone cements (ALBC). Methods: Based on the components, the bone cement samples were categorized as follows: the gentamicin combined with aloe-emodin group, the gentamicin combined with quercetin group, the gentamicin combined with curcumin group, the gentamicin combined with tannic acid group, the gentamicin group, the aloe-emodin group, the quercetin group, the curcumin group, and the tannic acid group. Using the disk diffusion test, we investigated the antibacterial properties of the bone cement material against Staphylococcus aureus (n = 4). We tested cell toxicity and proliferation using the cell counting kit-8 (CCK-8) and examined the biocompatibility of bone cement materials. Results: The combination of gentamicin with the four natural product extracts resulted in significantly larger diameters of inhibition zones compared to gentamicin alone, and the difference was statistically significant (P < 0.05). Except for the groups containing tannic acid, cells in all other groups showed good proliferation across varying time intervals without displaying significant cytotoxicity (P < 0.05). Conclusion: In this study, aloe-emodin, quercetin, curcumin, and tannic acid were capable of enhancing the in vitro antibacterial performance of gentamicin-loaded bone cement against S. aureus. While the groups containing tannic acid displayed moderate cytotoxicity in in vitro cell culture, all other groups showed no discernible cytotoxic effects.

3 October 2024 in Frontiers in Materials
Verified
Journal Article
Open access
PDF file
HLHao Lin
Hao Lin
ZGZhe Gao
Zhe Gao
LHLu-Yang Han
Lu-Yang Han
JCJian-jun Chu
Jian-jun Chu
YXYang Xu
Yang Xu
DSDian-Hong Shen
Dian-Hong Shen
A novel acrylic monomer containing a nitrofuran motif, referred to as long-chain nitrofuran methacrylate (LNFMA), is reported. In comparison to the previously reported nitrofuran methacrylate (NFMA), LNFMA has a longer side chain, and when incorporated into bone cement, the resulting LNFMA bone cement exhibits improved mechanical strength. At the same concentration, NFMA-5% cement has only 21.6 ± 1.3 MPa, while LNFMA-5% cement has a compressive strength of 42.64 ± 0.94 MPa. LNFMA bone cements exhibit antimicrobial activity against Staphylococcus aureus, with LNFMA-30% cement reaching 57.38% ± 5.53%. Moreover, LNFMA cement demonstrates excellent biocompatibility both in vitro and in vivo. The results showed that LNFMA monomer had optimized mechanical strength compared with previously reported NFMA monomers, and LNFMA bone cement had good antibacterial activity and biocompatibility.

17 September 2025 in RSC Advances
Verified
Journal Article
Open access
PDF file
YQYin-Yu Qi
Yin-Yu Qi
LHLu-Yang Han
Lu-Yang Han
LHLong-Xu Han
Long-Xu Han
WBWen-Han Bu
Wen-Han Bu
YXYang Xu
Yang Xu
JCJian-jun Chu
Jian-jun Chu
A sortase A inhibitor (SrtA I)-loaded bone cement (SLBC) containing 1-(3,4-dichlorophenyl)-3-(dimethylamino)propyl-1-one hydrochloride (AEEK1) was reported. Compared with gentamicin-loaded bone cement (GS cement), which is a widely used antibiotic-loaded bone cement in cemented total joint replacement (TJR), SLBC demonstrated a significantly prolonged effective antibacterial duration against both Staphylococcus aureus (S. aureus) and methicillin-resistant S. aureus (MRSA). The quasi-static compressive strength, maximum polymerization temperature, and setting time of SLBC were within the limits stated in the ISO 5833 standard and comparable to the corresponding values of GS cement. In vitro and in vivo experimental results confirmed the biocompatibility of SLBC and showed its easy injectability into porcine T12 vertebrae. Taken together, these findings suggest that SLBC may have potential for managing/treating prosthetic joint infections, which is a common complication in cemented TJR.

7 October 2025 in Materials Today Bio
Verified
Journal Article
Open access
YXYang Xu
Yang Xu
HLHao Lin
Hao Lin
YQYin-Yu Qi
Yin-Yu Qi
CWChen Wang
Chen Wang
LHLong-Xu Han
Long-Xu Han
JCJian-jun Chu
Jian-jun Chu
Antibacterial polymethylmethacrylate (PMMA) bone cement plays an important role in the prevention of periprosthetic joint infection (PJI). PMMA cement based on the immobilization of antibacterial comonomers has expanded the horizon of the PJI prophylaxis, but creating clinically-convenient and accessible cement remains challenging. Here, we have developed a nisin based point-of-care (POC) technology. This technology relies on the synergistic engineering of the natural peptide nisin and can be applied in the operating room. Nisin can act as a comonomer and be immobilized via naturally occurring dehydroalanine (Dha), thereby endowing the cement with antibacterial activity (up to 98 %), mechanical strength (compliant with ASTM F451 standard, minimum 70 MPa), as well as biocompatibility both in vitro and in vivo. The utility is further exemplified by a periprosthetic infection model in rats, with compatibility studies confirming its seamless integration with commercially available cements. All the raw materials are commercially available and easily accessible, and the usage process is consistent with that of clinical cement, showing excellent operability, thus expanding the toolbox for PJI prophylaxis.